Technology

#Events #Mass spectrometry / NMR #Technology

MOBILion Systems to showcase mass spectrometry product 

MOBILion Systems will showcase its first commercial High-Resolution Ion Mobility (HRIM) product, MOBIE, at the 69th Annual American Society for Mass Spectrometry (ASMS) conference.   Taking place from October 31 to November 4, the conference is the first in-person ASMS since 2019 and is being held in Philadelphia. Read More

#News

#Assays #Drug discovery #High throughput screening #Technology

Case study outlines how to create more therapeutic opportunity

Pairing the right small molecule library with innovative high-throughput screening creates more therapeutic opportunity, this SAMDI Tech case study shows.  Finding an encouraging drug lead that selectively engages a target of interest is the result of several matches that lead to successful drug discovery programmes, including: … Read More

#News

#AI / data analytics / healthtech / informatics #Drug discovery #Technology

Oncology is a major focus for AI drug discovery companies

The application of artificial intelligence (AI) in the drug discovery process is promising to drastically cut down timelines and costs of bringing new therapies to patients. The potential for AI to address these pain points has drawn significant attention from investors and players in the pharmaceutical industry. … Read More

#Market Reports #News #Trends & Analysis

#AI / data analytics / healthtech / informatics #Software #Technology

CDD launch free software tool 

Collaborative Drug Discovery (CDD) has released a free, full featured, standalone software tool: CDD Visualization. It is a browser-based application that allows scientists to visualise data and generate publication-ready graphs and plots.  If researchers are willing to share their data with the community, CDD hosts it for free. CDD… Read More

#News

#Cancer research #Proteomics #Technology #Webinar

Expert on opportunities in protein degradation

Many small molecule inhibitors have been approved as cancer therapeutics, but they can confer mutation-based drug resistance and many potential cancer targets remain ‘undruggable’.  One emerging cancer therapeutic strategy that shows promise for drug development is the use of targeted protein degradation (TPD). This approach has many advantages,… Read More

#News

#Biotechnology #Collaboration #Data #Technology #Webinar

Webinar reveals how to accelerate your drug discovery program 

This free-to-watch webinar, brought to you by Certara, reviews best practices for using technology to overcome challenges in order to accelerate discovery programs.  Drug discovery research requires understanding complex chemical, biological, logistical, and computational data from a variety of data sources. A key challenge for discovery scientists is efficiently… Read More

#Intelligence #News #Trends & Analysis

#AI #AI / data analytics / healthtech / informatics #Clinical trials #Technology

DDW AI expert exclusive: Boosting innovation in medicine 

In 18 months, vaccine research advanced AI in medicine by five to seven years. That’s cause for optimism — and investment — in the digital transformation of clinical development says Jeff Elton, CEO of Concerto HealthAI, who has extensive experience in this sector, and shares his insight with DDW.  In… Read More

#News

#Biopharma #Biotechnology #Collaboration #Life sciences #Technology

Why quantum computing in drug discovery needs to improve  

The Pistoia Alliance has released new results from a survey of 260 attendees from life science companies across the globe, finding that almost half classify their understanding of quantum computing (QC) technology at the beginner level (48%) only. This is followed by intermediate (29%), advanced (13%), and expert at… Read More

#News #Trends & Analysis

#AI #AI / data analytics / healthtech / informatics #Drug development #Drug discovery #Pharma #Technology

Exclusive interview: BenevolentAI on the future of AI

In what BenevolentAI considers a move that deepens its drug discovery and development expertise on its board, Dr John Orloff has been appointed as a Non-Executive Director. Dr Orloff joins the BenevolentAI board as it advances plans to scale its AI platform, partnerships and drug portfolio. DDW’s Megan Thomas speaks… Read More

#Editor's Choice #Exclusive Content #News #Opinion #Trends & Analysis

#Cancer research #Technology #Therapeutics #Tumour biology

First patient dosed in AVA6000 pro-Doxorubicin Phase I clinical trial

Avacta Group has dosed the first patient in its Phase I multicentre trial evaluating AVA6000, a novel pro-drug of Doxorubicin and the company’s first therapeutic based on its pre|CISION technology. The pre|CISION platform incorporates a substrate that is specifically cleaved by the protease fibroblast activation protein alpha (FAPa), which is… Read More

#News #Trending News

#Biotechnology #Drug discovery #Exscientia #Technology

Exscientia builds automated laboratories to expand pipeline

Exscientia has announced the opening of a 21,000 square foot expansion of its facilities at Oxford Science Park, UK, increasing capacity for its technology teams as well as significantly expanding its laboratory-based experimental capabilities in structural biology, biophysics and high-content pharmacology. In parallel, Exscientia is building a new 26,000 square… Read More

#News #Trending News

#AI / data analytics / healthtech / informatics #Biotechnology #Pharmaceuticals #Technology

AI-powered indication expansion partnership entered

Healx has partnered with Ono Pharmaceutical to leverage Healx’s indication expansion technology to identify new disease indications with high unmet needs that could be treated by Ono’s assets. Healx’s AI drug discovery platform, Healnet, integrates data from multiple sources – including biomedical research, patient insight, scientific literature and curated proprietary… Read More

#News

#Covid-19 #Immunology / Virology & Vaccines #Innovation #Technology

Neutralising SARS-CoV-2 infection with shark VNAR antibodies

While the global vaccine roll-out continues, the role of therapeutic antibodies to combat Covid-19 should not be overlooked. Now researchers have identified a novel class of antibodies that appears to have an ability to neutralise the original strain of SARS-CoV-2 and be able to block some of the recent mutations… Read More

#Covid-19 #Editor's Choice #Intelligence #News #Opinion

#Covid-19 #Drug delivery #Drug development #Drug discovery #Life sciences #Regulatory #Technology

How will UK life sciences vision impact medicine development and research?

The new UK Life Sciences Vision, developed with businesses and experts in the field, outlines seven critical missions that government, industry, the NHS, academia and medical research charities will work together on at speed to solve – from cancer treatment to tackling dementia. These missions will focus on preventing, diagnosing,… Read More

#News #Regulatory #Trending News